A Multicentre Study to Determine the Efficacy and Patient Acceptability of the Paxman Scalp Cooler to Prevent Hair Loss in Patients Receiving Chemotherapy

Alopecia is a distressing and common side-effect of chemotherapy, especially anthracycline- and taxane-containing regimen. A series of studies and reviews have considered scalp cooling as a means of reducing this side-effect without a definitive result. The aim of the study was to determine the efficacy and patient acceptability of scalp cooling using the Paxman Scalp Cooler. This was an open, non-randomised, observational study conducted at eight sites involving 94 patients. Alopecia was assessed using the World Health Organisation (WHO) grading system. Patient acceptability was assessed by questionnaire. Results were compiled by Scalp Cooling Assessment Groups using data from eight centres in the UK collected between 1997 and 2000. Use of the Paxman Scalp Cooler was adjudged a success for 89% of all patients using the WHO grading system for alopecia and for 87% of patients being specifically administered the commonly used 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen. When asked about degrees of comfort during the scalp-cooling process, 85% of patients described it as very comfortable, reasonably comfortable or comfortable, with only 15% of patients reporting a description of uncomfortable or very uncomfortable. Scalp cooling using the Paxman Scalp Cooler was found to be an effective technique with minimal side-effects for patients treated with commonly prescribed alopecia-inducing chemotherapy drugs.